response- ALTERATIONS IN CELLULAR PROCESSES
janejayson
responds-ALTERATIONSINCELLULARPROCESSES.docx
EA
Feb 25 12:31pm
Reply from Esther Amarachi Amaefule
Myasthenia Gravis: Pathophysiology and Clinical Correlation
The patient’s presentation is consistent with myasthenia gravis (MG), an autoimmune neuromuscular junction disorder characterized by fluctuating skeletal muscle weakness that worsens with activity and improves with rest. Classic features in this case include fatigable ptosis, diplopia, dysphagia, dysarthria, decreasing strength with repeated resistance testing, positive acetylcholine receptor (AChR) antibodies, a decremental response on repetitive nerve stimulation, and thymic hyperplasia. These findings reflect antibody-mediated disruption of postsynaptic neuromuscular transmission.
Genetic Associations
Myasthenia gravis is not caused by a single gene mutation but rather results from polygenic immune susceptibility. Variations in human leukocyte antigen (HLA) genes, particularly HLA-B8 and HLA-DR3 are strongly associated with AChR-positive MG and contribute to loss of immune tolerance. These genetic factors influence antigen presentation and increase the risk of autoantibody formation against neuromuscular junction proteins (Ropper et al., 2023). Additional immune-regulatory polymorphisms affecting T-cell signaling pathways further promote autoimmune activation and thymic abnormalities, which are commonly seen in early-onset disease (Verschuuren et al., 2022).
Why the Patient Presents with These Symptoms
The patient’s symptoms reflect impaired neuromuscular transmission due to reduced functional acetylcholine receptors. Extraocular muscles are affected early because they require sustained rapid firing, explaining ptosis and diplopia. Bulbar muscle involvement leads to difficulty chewing, swallowing, and nasal speech. The decline in strength with repeated resistance testing represents the hallmark fatigability of MG, while normal sensation and reflexes indicate that pathology is localized to the neuromuscular junction rather than peripheral nerves or muscle tissue (Ropper et al., 2023). Improvement with rest occurs because temporary recovery of acetylcholine availability allows short-term restoration of neuromuscular signaling.
Detailed Pathophysiological Mechanism
Myasthenia gravis is a type II antibody-mediated autoimmune disease targeting postsynaptic neuromuscular junction proteins. Autoantibodies bind ACh receptors and activate the complement cascade, leading to structural destruction of postsynaptic folds and reduction in receptor density. Antibody cross-linking also accelerates receptor internalization and degradation, while some antibodies directly block acetylcholine binding. Collectively, these mechanisms reduce the safety margin of neuromuscular transmission and impair end-plate potential generation (Verschuuren et al., 2022).
The thymus plays a central role in disease pathogenesis by promoting autoreactive T-cell activation and sustaining B-cell antibody production. Thymic hyperplasia, as seen in this patient, supports ongoing immune dysregulation and explains why thymectomy can improve disease outcomes (Narayanaswami et al., 2021). Electrophysiologic findings showing a decremental response on repetitive nerve stimulation reflect progressive failure of neuromuscular transmission with repeated impulses.
Interpretation of Blood Tests and Disease Progression
Elevated AChR antibodies confirm seropositive MG, the most common subtype, and indicate active immune-mediated receptor destruction. AChR positivity is associated with generalized disease, thymic abnormalities, and responsiveness to immunotherapy (Narayanaswami et al., 2021). Negative MuSK antibodies help distinguish this classic subtype from MuSK-associated MG, which often presents differently and responds to alternative therapies.
Normal CBC, CMP, TSH, ESR, and ANA results help exclude metabolic, endocrine, or systemic inflammatory causes of fatigue, reinforcing the neuromuscular junction as the primary disease site (Ropper et al., 2023). The decremental response on repetitive nerve stimulation provides objective evidence of impaired synaptic transmission, while thymic hyperplasia indicates persistent immune activation and potential benefit from thymectomy. Together, these findings suggest progression from ocular to generalized MG with ongoing autoimmune activity.
Clinical Significance
Understanding pathophysiology explains current treatment strategies. Acetylcholinesterase inhibitors improve neuromuscular transmission by increasing acetylcholine availability, while corticosteroids and other immunosuppressive therapies reduce antibody production. Emerging biologic therapies targeting complement pathways and neonatal Fc receptors represent major advances in disease management (DeHart-McCoyle et al., 2023; Verschuuren et al., 2022). Early recognition is essential because untreated disease may progress to respiratory muscle involvement and myasthenic crisis.
Conclusion
Myasthenia gravis represents an autoimmune disorder driven by genetic susceptibility, thymic dysfunction, and antibody-mediated destruction of postsynaptic acetylcholine receptors. The patient’s clinical features, laboratory findings, and imaging collectively demonstrate impaired neuromuscular transmission and evolving generalized disease. Integrating genetic risk, immunologic mechanisms, and diagnostic findings is critical for guiding treatment decisions and preventing life-threatening complications.
References
DeHart-McCoyle, M. P., Karam, C., & Howard, J. F. (2023). New and emerging treatments for myasthenia gravis. BMJ Medicine, 2(1), e000241. https://doi.org/10.1136/bmjmed-2022-000241
Narayanaswami, P., Sanders, D. B., Wolfe, G. I., Benatar, M., Cea, G., Evoli, A., Illa, I., Kuntz, N., Massey, J. M., Melms, A., Murai, H., Nicolle, M., Palace, J., Richman, D. P., & Verschuuren, J. (2021). International consensus guidance for management of myasthenia gravis: 2020 update. Neurology, 96(3), 114–122. https://doi.org/10.1212/WNL.0000000000011124
Ropper, A. H., Samuels, M. A., Klein, J. P., & Prasad, S. (2023). Disorders of neuromuscular transmission: Myasthenia gravis. In Adams and Victor’s Principles of Neurology (12th ed.). McGraw-Hill.
Verschuuren, J., Palace, J., Murai, H., Tannemaat, M. R., Kaminski, H. J., Bril, V., & Benatar, M. (2022). Advances in the treatment of myasthenia gravis. The Lancet Neurology, 21(7), 647–659. https://doi.org/10.1016/S1474-4422(21)00463-4
· Reply to post from Esther Amarachi Amaefule Reply
· Mark as Unread Mark as Unread
SB
Feb 25 8:40am| Last reply Feb 25 1:57pm
Reply from Salimata Bela
Alterations in Cellular Processes
· Which genetic mutations are commonly associated with the disease?
The disease diagnosis for the 34 year old patient based on the subjective and objective assessment findings is Myasthenia Gravis (MG). This is an autoimmune disease whose existence is significantly influenced by genetic polymorphisms that are related to the immune system. The genetic associations include specific Human Leukocyte Antigen (HLA) such as HLA-B8, DQB1*05, and DR3. These mutations which are associated with immune response increase the susceptibility to Acetylcholine Receptor (AChR) and Muscle-Specific Kinase (MuSK) positive myasthenia gravis (Yixian et al., 2025). The genes that are involved in the regulation of the T-cell function such as cytotoxic T-lymphocyte Associated-4 and the PTPN22 significantly contribute to early and late onset of myasthenia gravis (Dresser et al., 2021). The early onset of myasthenia gravis has also been associated with genetic variations in TNIP1 and TNFAIP3 genes.
· Why is the patient presenting with the specific symptoms described?
The 34 year old is presenting with the specific symptoms because of the loss of nerve and muscle communication at the neuromuscular junction. Ptosis and diplopia that the 34 year old is experiencing is a result of the reduced acetylcholine which the upward gauze almost depletes causing the fatigue. The worsening of symptoms towards end of the day that are only improved by rest is caused by progressing autoantibody accumulation that causes functional receptor depletion causing weakness that is relieved by resting. The slurred speech, dysphagia and difficulty chewing meat is caused by antibodies in the bulbar region which cause muscle fatigue with repeated use of the muscles (Dresser et al., 2021). The decrease of muscle strength to 4/5 with repetitive resistance is caused by the decline of acetylcholine receptors which affects strength of muscle contraction (Kaminski et al., 2024). It is important to point out that thymic hyperplasia for this patient is associated with production of autoantibodies that lead to myasthenia gravis.
· Discuss the pathophysiological mechanisms of the disease in detail.
The pathophysiological mechanisms of myasthenia gravis is determined by the antibodies that are present. The autoantibodies involved include the IgG1/IgG3 against nicotinic acetylcholine receptors (AChR) or IgG4 against MuSK/LRP4 which cause destruction and blocking of the postsynaptic receptors at the neuromuscular junction (Dresser et al., 2021). The IgG1 and IgG3 autoantibodies bind the acetylcholine receptor causing the formation of a membrane attack complex in the skeletal muscle postsynaptic membrane. This causes significant degradation of these receptors which causes loss of muscle contraction leading to fatigue and weakness that fluctuates. Myasthenia gravis that is associated with MusK or LPR-4 involves IgG4 antibodies which bind to the protein complex in the neuromuscular junction. The inhibition of the MuSK-LRP4-Agric complex causes acetylcholine receptors to reduce because this complex is involved in the clustering and distribution of the receptor (Kaminski et al., 2024). The reduced number of the receptors makes it difficult for acetylcholine to generate adequate postsynaptic potential leading to muscle weakness which only worsens with repeated use of the muscle.
· What do the blood test results tell us about the disease and disease progression?
The blood test results for the 34 year old include normal CMP and CBC, negative ANA, ESR 10mm/hour, TSH 2.1 µIU/mL, Elevated acetylcholine receptors, and negative anti-Musk antibodies. These results show that the direct cause of the myasthenia gravis disease is the acetylcholine receptor antibodies because the blood test results show that they are elevated. This explains the patient’s ptosis, chewing difficulties, dysphagia and diplopia. The negative ant-MuSK antibodies help rule out the Musk-LRP-4 complex antibodies as the cause of the disease. It is important to point out that the chest CT, although not a blood test, revealed thymic hyperplasia which is a common finding in myasthenia gravis – related acetylcholine receptor antibodies. The results show that the disease is transitioning from ocular to generalized as the symptoms are beyond just ptosis as they now include slurred speech and dysphagia. This shows the effect of acetylcholine receptor autoantibody (Gilhus et al., 2024). It is important to point out that the patient’s high antibody titers is an indication of a possible faster progression with severe symptoms. The rising levels of acetylcholine titers even with immunotherapy is likely to cause flare-ups.
References
Dresser, L., Wlodarski, R., Rezania, K., & Soliven, B. (2021). Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations. Journal of Clinical Medicine, 10(11), 1 – 17. https://doi.org/10.3390/jcm10112235Links to an external site. .
Gilhus, N. E., Andersen, H., Andersen, L. K., Boldingh, M., Laakso, S., Leopoldsdottir, M. O., Madsen, S., Piehl, F., Popperud, T. H., Punga, A. R., Schirakow, L., & Vissing, J. (2024). Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. European Journal of Neurology, 31(5), 1 – 13. https://doi.org/10.1111/ene.16229Links to an external site. .
Kaminski, H. J., Sikorski, P., Coronel, S. I., & Kusner, L. L. (2024). Myasthenia gravis: the future is here. Journal of Clinical Investigation, 134(12), 1 – 13. https://doi.org/10.1172/jci179742Links to an external site. .
Yixian, Z., Hai, W., Xiuying, L., & Jichun, Y. (2025). Advances in the genetics of myasthenia gravis: insights from cutting-edge neuroscience research. Frontiers in Medicine, 11, 1 – 7. https://doi.org/10.3389/fmed.2024.1508422yLinks to an external site. .
· Expand discussion thread from Salimata Bela
3 Replies, 3 Unread
3 Replies, 3 Unread
· Reply to post from Salimata Bela Reply
· Mark as Unread Mark as Unread
